Safely Stopping Bladder Medications in Parkinson Disease
Part of Brain & nervous system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether people with Parkinson disease can safely stop taking antimuscarinic medications (commonly used for overactive bladder) under medical supervision. The goal is to see if stopping these medications might help with thinking and memory problems that can be side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years or older
- You have been diagnosed with Parkinson disease by a movement disorder specialist
- You have been taking an antimuscarinic bladder medication (like oxybutynin or solifenacin) by mouth for at least 3 months
- You can complete online surveys and participate in phone or video calls with the research team
- You have no serious untreated high blood pressure, recurrent bladder infections, or severe kidney or liver disease
- You do not have significant memory problems or psychiatric conditions that would prevent you from understanding and consenting to the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called mirabegron, a behavioral program, or both can improve urinary symptoms (like urgency and leakage) in people with Parkinson's disease. It may help you have better bladder control and daily comfort.
This trial tests if botulinum toxin A injections can help control overactive bladder symptoms in people with Parkinson's disease who haven't gotten enough relief from standard bladder medications. It aims to see if the treatment is safe and effective.
This study tests medicines to reduce “urgency” urine leakage (when you suddenly feel you must go) and to see whether improving bladder control also helps overall mental and physical health. You may be eligible if you have had these symptoms for at least 3 months and can follow the study plan.
This trial tests whether pyridostigmine can improve constipation symptoms in people with Parkinson’s disease. If you have Parkinson’s and functional constipation (with infrequent bowel movements), this study may offer a new medication option and closely track your bowel function.
This trial tests whether simple blood tests can predict how well a woman with overactive bladder will respond to the medication mirabegron (also called Myrbetriq). If successful, doctors may be able to choose the right treatment earlier.
This study uses MRI to understand how blood pressure is controlled in people with Parkinson's disease who have orthostatic hypotension (a drop in blood pressure when standing). It may help find better treatments for this common symptom.
Hear when a new Parkinson Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.